- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06595238
En studie av deltakere med fedme eller overvekt med minst én vektrelatert komorbiditet (APRICUS)
En fase IIb randomisert, dobbeltblind, placebokontrollert studie for å evaluere effektiviteten, sikkerheten og toleransen til AZD6234 hos deltakere som lever med fedme eller overvekt med komorbiditet
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 36 weeks, in male and female participants of at least 18 years of age who are living with obesity (body mass index [BMI] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) and at least one weight-related comorbidity
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The study will comprise of:
A screening period of maximum 28 days
A treatment period of 36 weeks
A follow up period after last dose of study drug
This study will consist of 4 cohorts. Approximately 231 eligible participants will be randomized to AZD6234 or placebo
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
-
Heidelberg, Australia, 3081
- Research Site
-
Maroochydore, Australia, 4556
- Research Site
-
Maroubra, Australia, 2035
- Research Site
-
Merewether, Australia, 2291
- Research Site
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 5G8
- Research Site
-
Sarnia, Ontario, Canada, N7T 4X3
- Research Site
-
Stouffville, Ontario, Canada, L4A1H2
- Research Site
-
Toronto, Ontario, Canada, M3J 0K2
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canada, H4N 2W2
- Research Site
-
Sherbrooke, Quebec, Canada, J1L 0H8
- Research Site
-
-
-
-
Alabama
-
Mobile, Alabama, Forente stater, 36608
- Research Site
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85044
- Research Site
-
-
California
-
Long Beach, California, Forente stater, 90815
- Research Site
-
-
Florida
-
Hialeah, Florida, Forente stater, 33012
- Research Site
-
Largo, Florida, Forente stater, 33777
- Research Site
-
Orlando, Florida, Forente stater, 32825
- Research Site
-
Tampa, Florida, Forente stater, 33606
- Research Site
-
-
Georgia
-
Woodstock, Georgia, Forente stater, 30189
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46260
- Research Site
-
-
Maryland
-
Lutherville-Timonium, Maryland, Forente stater, 21093
- Research Site
-
-
Mississippi
-
Gulfport, Mississippi, Forente stater, 39503
- Research Site
-
Ridgeland, Mississippi, Forente stater, 39157
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64111
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68134
- Research Site
-
-
New Hampshire
-
Portsmouth, New Hampshire, Forente stater, 03801
- Research Site
-
-
North Carolina
-
Statesville, North Carolina, Forente stater, 28625
- Research Site
-
-
South Carolina
-
North Charleston, South Carolina, Forente stater, 29405
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37938
- Research Site
-
-
Texas
-
Austin, Texas, Forente stater, 78731
- Research Site
-
Dallas, Texas, Forente stater, 75230
- Research Site
-
Port Arthur, Texas, Forente stater, 77642
- Research Site
-
San Antonio, Texas, Forente stater, 78249
- Research Site
-
San Antonio, Texas, Forente stater, 78231
- Research Site
-
-
-
-
-
Chūōku, Japan, 103-0027
- Research Site
-
Chūōku, Japan, 104-0031
- Research Site
-
Shinjuku-ku, Japan, 160-0008
- Research Site
-
Suita-shi, Japan, 565-0853
- Research Site
-
-
-
-
-
Hull, Storbritannia, HU3 2PA
- Research Site
-
Leicester, Storbritannia, Le5 4PW
- Research Site
-
Penarth, Storbritannia, CF64 2XX
- Research Site
-
Rotherham, Storbritannia, S65 1DA
- Research Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adults ≥ 18 years of age
- BMI of (a) ≥ 30 kg/m2, or (b) ≥ 27kg/m2 and have a current diagnosis of at least 1 weight-related comorbidities (treated or untreated)
- A stable body weight for 3 months prior to Screening (±5% body weight change)
Exclusion Criteria:
- Have obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome
- Has received prescription or non-prescription medication for weight loss within the last 3 months prior to Screening
- Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier)
- History of type 1 diabetes mellitus or T2DM
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Arm 1
Dose 1 |
IMP injected subcutaneously, once a week. Unit dose strength as per CSP |
|
Eksperimentell: Arm 2
Dose 2 |
IMP injected subcutaneously, once a week. Unit dose strength as per CSP |
|
Eksperimentell: Arm 3
Dose 3 |
IMP injected subcutaneously, once a week. Unit dose strength as per CSP |
|
Placebo komparator: Arm 4
Placebo - Dose matched with each Experimental arm |
Placebo matching IMP dose injected subcutaneously, once a week. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percent change in body weight from baseline to week 26
Tidsramme: 26 weeks
|
To determine whether AZD6234 is superior to placebo for weight loss |
26 weeks
|
|
Weight loss ≥ 5% from baseline weight to week 26
Tidsramme: 26 weeks
|
To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 5% from baseline |
26 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Weight loss ≥ 5% from baseline to week 36
Tidsramme: 36 weeks
|
To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 5% from baseline |
36 weeks
|
|
Weight loss ≥ 10% from baseline to week 36
Tidsramme: 36 weeks
|
To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 10% from baseline |
36 weeks
|
|
Percent change in body weight from baseline to week 36
Tidsramme: 36 weeks
|
To determine whether AZD6234 is superior to placebo for weight loss |
36 weeks
|
|
Absolute change in body weight (kg) from baseline to week 26 and week 36
Tidsramme: week 26 and week 36
|
To determine whether AZD6234 is superior to placebo for absolute weight loss |
week 26 and week 36
|
|
AZD6234 plasma concentrations
Tidsramme: Week 43
|
To characterise the PK of AZD6234 |
Week 43
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- D8750C00004
- 2024-514000-13-00 (Registeridentifikator: EU CT number)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-delingstidsramme
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Tilgangskriterier for IPD-deling
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .